With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

This can be explained by the first generation weight loss product that Novo Nordisk had launched, Saxenda (liraglutide), which had been approved by the FDA to treat obesity in 2014. The product ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and ...